Changeflow GovPing Healthcare & Life Sciences Nucleoside Compound for Feline Infectious Perit...
Priority review Rule Added Final

Nucleoside Compound for Feline Infectious Peritonitis, EP4328227A1

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published application EP4328227A1 on April 15, 2026, covering a nucleoside compound and its therapeutic application in the treatment of Feline Infectious Peritonitis (FIP). The applicant is Vigonvita Life Sciences Co., Ltd., with inventors LEI Yang, CAO Gang, and HU Rong. The application covers C07D 487/04 heterocyclic compounds and is designated across 31 European states including DE, FR, GB, IT, NL, ES, PL, and SE.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 63 changes logged to date.

Notice an inaccuracy or want this record removed? Email corrections@changeflow.com . We respond within 48 hours and honor reasonable requests. See our editorial standards .

What changed

The EPO published EP4328227A1, a patent application for a nucleoside compound and its therapeutic use against Feline Infectious Peritonitis (FIP), a fatal coronavirus disease in cats. The application claims priority under IPC classifications C07D 487/04 (heterocyclic compounds), A61K 31/53 and A61K 31/5377 (pharmaceutical compositions), and A61P 31/14 and A61P 29/00 (antiviral and anti-inflammatory indications). Vigonvita Life Sciences Co., Ltd. is the applicant.

Pharmaceutical and veterinary biotechnology companies engaged in antiviral nucleoside research or FIP therapeutics should monitor this application's prosecution. Competitors developing similar compounds may need to conduct freedom-to-operate analysis in the 31 designated European states once the application proceeds to grant.

Archived snapshot

Apr 25, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

NUCLEOSIDE COMPOUND AND APPLICATION THEREOF IN THE TREATMENT OF FELINE INFECTIOUS PERITONITIS

Publication EP4328227A1 Kind: A1 Apr 15, 2026

Applicants

Vigonvita Life Sciences Co., Ltd.

Inventors

LEI, Yang, CAO, Gang, HU, Rong

IPC Classifications

C07D 487/04 20060101AFI20241113BHEP A61K 31/53 20060101ALI20241113BHEP A61K 31/5377 20060101ALI20241113BHEP A61P 31/14 20060101ALI20241113BHEP A61P 29/00 20060101ALI20241113BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4328227A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent licensing Drug development Nucleoside research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Compliance frameworks
GxP
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!